![]() Music |
![]() Video |
![]() Movies |
![]() Chart |
![]() Show |
![]() |
Considerations for drug development in hematological oncology (VJHemOnc – Video Journal of Hematology \u0026 HemOnc) View |
![]() |
The FDA’s (HPR) View |
![]() |
Richard Pazdur, FDA Office of Hematology and Oncology Products (OHOP) (Oncoletter) View |
![]() |
Use of Surrogate Endpoints in Oncology (Duke Margolis) View |
![]() |
Economic Trade-offs in Cancer Drug Pricing (Mayo Proceedings) View |
![]() |
The Future Use of Complex Biomarkers: Fireside Chat (Friends of Cancer Research) View |
![]() |
Current concepts and future developments in T-cell-based immunotherapy of AML (VJHemOnc – Video Journal of Hematology \u0026 HemOnc) View |
![]() |
MRD in myeloma: the need for sensitive and standardized measures (VJHemOnc – Video Journal of Hematology \u0026 HemOnc) View |
![]() |
Drug Development and Implementation: Blood Drop Series at ASH-a-Palooza 2019 (American Society of Hematology) View |
![]() |
Phases of Clinical Trials - Sarah Cannon (Sarah Cannon Research Institute) View |